EUVIMEDEUVIMED entdecken
Crossref

SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant

Alvin Ho-Kwan Cheung, Kit-Yee Wong, Shuk-Ling Chau, Fuda Xie, Zeta Mui, Gordon Yuan-Ho Li, Molly Siu Ching Li, Joanna Tong, Calvin Sze-Hang Ng, Tony S Mok, Wei Kang, Ka-Fai To

Pathology · 2024-06 · 56 (4) · 504-515

DOI: 10.1016/j.pathol.2023.12.414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology, 2024-06. Verfasst von Alvin Ho-Kwan Cheung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of …. Hauptthemen laut MEDLINE: Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, DNA Helicases, Nuclear Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SMARCA4 mutation has emerged as a marker of poor prognosis in lung cancer and has potential predictive value in cancer treatment, but recommendations for which patients require its investigation are lacking. We comprehensively studied SMARCA4 alterations and the clinicopathological significance in a large cohort of immunohistochemically-subtyped non-small cell lung cancer (NSCLC). A total of 1416 patients was studied for the presence of SMARCA4 deficiency by immunohistochemistry (IHC). Thereafter, comprehensive sequencing of tumours was performed for 397 of these patients to study the mutational spectrum of SWI/SNF and SMARCA4 aberrations. IHC evidence of SMARCA4 deficiency was found in 2.9% of NSCLC. Of the sequenced tumours, 38.3% showed aberration in SWI/SNF complex, and 9.3% had SMARCA4 mutations. Strikingly, SMARCA4 aberrations were much more prevalent in large cell carcinoma (LCC) than other histological tumour subtypes. SMARCA4-deficient and SMARCA4-mutated tumours accounted for 40.5% and 51.4% of all LCC, respectively. Multivariable analyses confirmed SMARCA4 mutation was an independent prognostic factor in lung cancer. The immunophenotype of a subset of these tumours frequently showed TTF1 negativity and HepPAR1 positivity. SMARCA4 mutation or its deficiency was associated with positive smoking history and poor prognosis. It also demonstrated mutual exclusion with EGFR mutation. Taken together, the high incidence of SMARCA4 aberrations in LCC may indicate its diagnostic and prognostic value. Our study established the necessity of SMARCA4 IHC in the identification of SMARCA4-aberrant tumours, and this may be of particular importance in LCC and tumours without known driver events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Large CellCarcinoma, Non-Small-Cell LungDNA HelicasesNuclear ProteinsTranscription FactorsFemaleHumansMaleBiomarkers, TumorImmunohistochemistryLung NeoplasmsMutationPrognosis

Stichwörter der Autor:innen

Lung cancerSMARCA4SWI/SNF complex

Substanzen

Biomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease…
  • Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

Zitieren

APA

Cheung, A. H., Wong, K. Y., Chau, S. L., Xie, F., Mui, Z., Li, G. Y., Li, M. S. C., Tong, J., Ng, C. S., Mok, T. S., Kang, W., & To, K. F. (2024). SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathology, 56(4), 504-515. https://doi.org/10.1016/j.pathol.2023.12.414

Vancouver

Cheung AH, Wong KY, Chau SL, Xie F, Mui Z, Li GY, et al. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathology. 2024;56(4):504-515. doi:10.1016/j.pathol.2023.12.414

BibTeX
@article{Cheung2024,
  author = {Cheung, Alvin Ho-Kwan and Wong, Kit-Yee and Chau, Shuk-Ling and Xie, Fuda and Mui, Zeta and Li, Gordon Yuan-Ho and Li, Molly Siu Ching and Tong, Joanna and Ng, Calvin Sze-Hang and Mok, Tony S and Kang, Wei and To, Ka-Fai},
  title = {SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant},
  journal = {Pathology},
  year = {2024},
  volume = {56},
  number = {4},
  pages = {504--515},
  doi = {10.1016/j.pathol.2023.12.414}
}
Kostenlos starten →